TEXTILES.ORG
Nufabrx, Charlotte, N.C., announced that the company is expanding access to its non-opioid pain relief products across federal health care systems and has secured new funding to support continued growth and innovation.
The company announced its inclusion on TrillaMed’s Pharmacy (FSS) and DAPA contracts, increasing availability of its time-released pain relief solutions across federal providers, including the Department of Defense, Veterans Affairs, Indian Health Service and Bureau of Prisons.
The contracts—DAPA Med/Surg Contract #SP0200-14-H-0017 and FSS Pharma Contract #V797D-70148— streamline procurement and access for federal facilities. Field support and clinical engagement will be led by Veterans Medical Distributors through its local network.
“With the addition of Nufabrx to TrillaMed’s contract portfolio, federal providers now have easier access to a clinically impactful, non-opioid solution,” says Debbie Grout, president of business development at Veterans Medical Distributors. “We are positioned to drive education, adoption and improved patient outcomes at the facility level.”
Nufabrx’s platform delivers medication through compression textiles, providing targeted, time-released relief without the systemic side effects associated with oral treatments. The products combine over-the-counter pain relief with compression therapy and are designed for all-day use, maintaining effectiveness through up to 15 washes.
The solutions support a range of clinical applications, including orthopaedics, podiatry, physical therapy, primary care and chronic conditions such as arthritis and neuropathy.
Separately, Nufabrx announced it has raised $5 million in an oversubscribed funding round led by Meltzer Capital. The investment will support product innovation, distribution expansion and increased brand awareness.
“Meltzer Capital is thrilled to lead the financing round in Nufabrx, which will enable more people to access pain relief without opioids,” says David Meltzer, founder and CEO of Meltzer Capital.
Nufabrx develops FDA-registered compression products that deliver capsaicin directly to the skin, offering a wearable, targeted approach to pain management and recovery.
“This investment marks an important milestone for Nufabrx,” says Glenn Normoyle, CEO of Nufabrx. “Meltzer Capital’s commitment validates our technology and long-term vision as we continue to grow.”